The Bruestle Group - Neuroimmunology and Multiple Sclerosis

The Bruestle Group - Neuroimmunology and Multiple Sclerosis, is focusing on innate and adaptive immune responses in the central nervous system. A special interest of this group is in type 3 immune responses including the CD4 subset of inflammatory Th17 cells, neutrophils and dendritic cells. Using genetically modified mouse strains they analyse the differentiation and effector function of these cells in vitro as well as in in vivo models. In collaboration with different industry partners, they further investigate these immune cells as new targets for improved therapies in the context of Multiple Sclerosis. The Bruestle Group is also part of “Our Health in Our Hands” a transdisciplinary research program developing personalised approaches for the management of chronic autoimmune conditions such as MS.

Enquiries are welcome from potential Honours or PhD students with an interest in autoimmunity and T cell biology. A variety of projects are available within all of the areas of research undertaken by this Group.

Filter by keyword

Selected Publications:

Evita Bothur*, .., Anne Brüstle, et al. Antigen receptor-mediated depletion of FOXO3 in induced T-lymphocytes via PTPN2 and FOXO. Nat Comms. doi:10.1038/ncomms9576

Brüstle A*, Brenner D*, MALT1 is an intrinsic regulator of regulatory T cells. Cell Death Differ. doi: 10.1038/cdd.2015.104. [Epub ahead of print]

Harris IS, ..., Brüstle A, et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. . 2015 Feb 9;27(2):211-22. doi: 10.1016/j.ccell.2014.11.019.

Brüstle A. Is DUBA putting the brake on Th17 cells? Immunol Cell Biol. Feb:93(2):111-2 (2015)

Parish IA,..., Brüstle A, et al. Chronic viral infection promotes sustained Th1-derived immunoregulatory IL-10 via BLIMP-1. J Clin. Invest. 124(8): 3455-68 (2014)

Brenner D*, Brüstle A*, et al. Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells.. 111(3):1060-5 (2014)

Huber M*, Heink S*,..., Brüstle A, et al. J Clin Invest. 123(1):247-60 (2013)

Brüstle A*, Brenner D*, et al. The NF-kB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J Clin Invest. 122(12):4698-709 (2012)

Sasaki M*, Knobbe CB*, ..., Brüstle Aet al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 488(7413):656-9 (2012)

Bollig N, Brüstle A, et al. Transcription factor IRF4 determines germinal center formation through follicular T-helper cell differentiation. 109(22):8664-9 (2012)

Reardon C*, Lechmann M*, Brüstle A, et al. TSLP-induced expression of the endogenous inhibitory enzyme SLPI mediates recovery from colonic inflammation. . 35(2):223-35 (2011)

Huber M, Brüstle A, et al. IRF4 is essential for IL-21-mediated induction, amplification and stabilisation of the TH17 phenotype. . 105(52):20846-51(2008).

Brüstle A, Heink S, Huber M, Rosenplänter C, Stadelmann C, Yu P, Arpaia E, Mak TW, Kamradt T, Lohoff M, The development of inflammatory T(H)-17 cells requires IRF4. Nat Immunol. (9):958-66 (2007).